



14 August 2020

Sydney, Australia

## Notice under Section 708A(5)(E) of the Corporations Act 2001 (Cth)

**Sydney, 14 August 2020:** Noxopharm Limited (ASX: NOX) has today issued as per the Appendix 2A lodged earlier today:

- (a) 25,304,819 Options over Fully Paid Ordinary Shares (**Underwriter Options**) as approved by shareholders at today's Extraordinary General Meeting; and
- (b) 40,000 Ordinary Shares further to the exercise of 40,000 options (ASX: NOXO).

NOX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

- 1 The New Options were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2 As at the date of this notice, NOX has complied with:
  - (a) The provisions of Chapter 2M of the Corporations Act as they apply to NOX; and
  - (b) Section 674 of the Corporations Act.
- 3 As at the date of this notice, there is no information that is "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

A handwritten signature in black ink, appearing to read "D. Franks".

David Franks  
Company Secretary

-----



## About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on treating cancer with Veyonda®, its lead drug candidate.

Veyonda® is a dual-acting oncotoxic and immuno-oncology drug designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapy, radiotherapy and immuno-oncology drugs. The drug acts by harnessing the body's immune system to inflict damage on cancer cells in the body and has shown promise in treating a broad spectrum of cancers.

Noxopharm also has an active research and development (R&D) program for additional drug candidates and is the major shareholder of US biotechnology company Nyrada Inc. (ASX:NYR).

To learn more please visit: <https://www.noxopharm.com/>

### Investor & Corporate enquiries:

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

### Company Secretary:

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### Media Enquiries

Julia Maguire

The Capital Network

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

T: + 61 2 8999 3699

*The Board of Directors of Noxopharm has approved the release of this document to the market.*

### Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.